TheHealthPlan 1110 Main Street, Wheeling, WV 26003-2704 • 1.800.624.6961 • healthplan.org

Non-Invasive Prenatal (NIPT) Genetic Testing for Identification of Chromosomal Aneuploidy

Medical Policy Guidance:

Recommendation

Medically Necessary

- Non-invasive prenatal genetic testing for identification of chromosomal aneuploidy.

INCLUSIONS

1. Women with high-risk singleton pregnancies.
2. Nucleic acid sequencing-based testing of maternal plasma for fetal aneuploidy testing for:
   a. Trisomy 21, and concurrent testing for
   b. Trisomy 13
   c. Trisomy 18
3. In women with ANY of the following criteria:
   a. Maternal age 35 years or older at delivery; OR
   b. Fetal ultrasonographic findings indicating increased risk of aneuploidy; OR
   c. History of previous pregnancy with a trisomy; OR
   d. Standard serum screening test positive for aneuploidy (See CPT Codes 81508-81512 for underlying tests); OR
   e. Parental balanced Robertsonian translocation with increased risk of fetal trisomy 13 or trisomy 21.

EXCLUSIONS

1. In women with average-risk singleton pregnancies.
2. In women with twin or multiple pregnancies.
3. Sex Chromosomal aneuploidies (SCA).

LIMITATIONS

None

APPLICABLE CODES

This list may not be all inclusive.

CODE	FULL DESCRIPTION
81420	Fetal chromosomal aneuploidy (e.g., trisomy 21, monosomy X) genomic sequence analysis panel, circulating cell-free fetal DNA in maternal blood, must include analysis of chromosomes 13, 18, and 21
81422	Fetal chromosomal microdeletion(s) genomic sequence analysis (e.g., DiGeorge syndrome, Cri-du-chat syndrome), circulating cell-free fetal DNA in maternal blood
81507	Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy
81508	Biochemical assay of two proteins including PAPP-A and hCG utilizing maternal serum for fetal congenital abnormality
81509	Biochemical assay of three analytes including AFP, uE3 and hCG utilizing maternal serum for fetal congenital abnormality
81510	Biochemical assay of three analytes including AFP, uE3 and hCG utilizing maternal serum for fetal congenital abnormality
81511	Biochemical assay of four analytes including AFP, uE3, hCG and DIA utilizing maternal serum for fetal congenital abnormality
81512	Biochemical assay of five analytes including AFP, uE3, total hCG, hyperglycosylated hCG and DIA utilizing maternal serum for fetal congenital abnormality
88271	Molecular cytogenetics using DNA probe
0009M	Fetal aneuploidy (trisomy 21, and 18) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy (VisibiliT™, Sequenom Center for Molecular Medicine, LLC)
0060U	Twin zygosity, genomic targeted sequence analysis of chromosome 2, using circulating cell-free fetal DNA in maternal blood
0168U	Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma without fetal fraction cutoff, algorithm reported as a risk score for each trisomy